Pre-made Bimagrumab benchmark antibody ( Whole mAb, anti-ACVR2B therapeutic antibody, Anti-ACTRIIB/ActR-IIB/HTX4 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-069
Pre-Made Bimagrumab biosimilar, Whole mAb, Anti-ACVR2B Antibody: Anti-ACTRIIB/ActR-IIB/HTX4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Bimagrumab biosimilar, Whole mAb, Anti-ACVR2B Antibody: Anti-ACTRIIB/ActR-IIB/HTX4 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||5nhr:HL:AB|
|99% SI Structure||5nhw:HL/5nh3:HL:IM/5ngv:HL|
|95-98% SI Structure||None|
|Conditions Active||Cachexia;Muscular atrophy;Type 2 diabetes mellitus|
|Conditions Discontinued||Inclusion body myositis|
|Development Tech||MorphoSys HuCAL Phage Display|